Glionova Therapeutics Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 2

Employees

  • Latest Deal Type
  • Liquidation

Glionova Therapeutics General Information

Description

Developer of cancer prevention therapies based in Stockholm, Sweden. The company offers a small-molecule oncolytic drug targeting specific vulnerabilities in tumor cells, enabling patients suffering from glioblastoma to help recover from their illness.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Corporate Office
  • Care of Svenska Standardbolag AB
  • Box 292, Falun
  • 111 53 Stockholm
  • Sweden

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Glionova Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Bankruptcy: Liquidation 17-Jan-2019 00.000 Completed Bankruptcy: Liquidation
2. Grant 20-Nov-2014 00000 00.000 Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 12-Nov-2014 $5.75M $5.75M Completed Pre-Clinical Trials
To view Glionova Therapeutics’s complete valuation and funding history, request access »

Glionova Therapeutics Patents

Glionova Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3064493-A1 Crystalline forms of (r)-(2-(4-chlorophenyl)quinolin-4-yl)((s)-(piperidin-2-yl)methanol Inactive 06-Mar-2015 0000000000 0
EP-3064205-A1 Therapeutic use of isomeric forms of 2-(4-chlorophenyl)quinolin-4-yl)(piperidin-2-yl)methanol Inactive 06-Mar-2015 000000000 0
AU-2014316783-A1 Compounds and use for treating cancer Inactive 09-Sep-2013 00000000000
JP-2016534129-A Compounds and uses for treating cancer Pending 09-Sep-2013 0000000000
EP-3043801-A2 Compounds and use for treating cancer Inactive 09-Sep-2013 C07D401/06
To view Glionova Therapeutics’s complete patent history, request access »

Glionova Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Glionova Therapeutics FAQs

  • When was Glionova Therapeutics founded?

    Glionova Therapeutics was founded in 2014.

  • Who is the founder of Glionova Therapeutics?

    Lars Hammarstrom Ph.D is the founder of Glionova Therapeutics.

  • Where is Glionova Therapeutics headquartered?

    Glionova Therapeutics is headquartered in Stockholm, Sweden.

  • What is the size of Glionova Therapeutics?

    Glionova Therapeutics has 2 total employees.

  • What industry is Glionova Therapeutics in?

    Glionova Therapeutics’s primary industry is Biotechnology.

  • Is Glionova Therapeutics a private or public company?

    Glionova Therapeutics is a Private company.

  • What is Glionova Therapeutics’s current revenue?

    The current revenue for Glionova Therapeutics is 000000.

  • How much funding has Glionova Therapeutics raised over time?

    Glionova Therapeutics has raised $5.75M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »